CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Atara Biotherapeutics, Inc.  (ATRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ATRA's Income from Cont. Operations Growth by Quarter and Year

Atara Biotherapeutics,'s Income from Cont. Operations results by quarter and year




ATRA Income from Cont. Operations (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - -35.31 -18.24 -21.25
III Quarter September -58.36 -31.10 -25.37 -11.87
II Quarter June -50.88 -27.43 -18.88 -14.95
I Quarter March -41.44 -25.65 -16.56 -9.16
FY   -150.68 -119.49 -79.05 -57.23



ATRA Income from Cont. Operations third quarter 2018 Y/Y Growth Comment
Atara Biotherapeutics, Inc. in the third quarter recorded loss from continued operations of $ -58.36 millions.

According to the results reported in the third quarter, Atara Biotherapeutics, Inc. achieved the best Income from Cont. Operations growth in Biotechnology & Drugs industry. While Atara Biotherapeutics, Inc.' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter.




ATRA Income from Cont. Operations ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Atara Biotherapeutics,'s third quarter 2018 Income from Cont. Operations $ 0.00 millions ATRA's Income Statement
Atara Biotherapeutics,'s third quarter 2017 Income from Cont. Operations $ 0.00 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Income from Cont. Operations Growth >>


ATRA Income from Cont. Operations (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Atara Biotherapeutics,'s Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's III. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -58.36 millions by Atara Biotherapeutics, Inc. come out even more unfavourable if you take a look at loss from continued operations -50.88 millions in the second quarter.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Income from Cont. Operations growth. While Atara Biotherapeutics,'s Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's III. Quarter Q/Q Income from Cont. Operations Comment
Current accomplishment of -58.36 millions by Atara Biotherapeutics, Inc. look even worse considering the -50.88 millions loss from continued operations in the second quarter.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Income from Cont. Operations growth. While Atara Biotherapeutics,'s Income from Cont. Operations growth quarter on quarter, overall rank is .


Atara Biotherapeutics,'s 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
Cumulative Income from Cont. Operations 12 Months Ending $ -186.00 $ -158.74 $ -135.28 $ -119.49 $ -102.41
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Atara Biotherapeutics, Inc.' has realized cumulative trailing twelve months loss from continued operations of $ -186 millions in the Sep 30 2018 period.
The results are worsening as the cumulative loss from continued operations is inflating from $ -158.74 millions in TTM ending quarter Jun 30 2018 and $ -50.88 millions from the TTM period ending Sep 30 2017 Livia Svensson wrote.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Atara Biotherapeutics, Inc.' has realized cumulative trailing twelve months loss from continued operations of $ -186 millions in the Sep 30 2018 period.
The results are worsening as the cumulative loss from continued operations is becoming larger from $ -158.74 millions for the period from Jun 30 2018 to Sep 30 2017 and $ -50.88 millions for the twelve months ending in the quarter a year ago Livia Svensson told.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Drugs Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
ATRA's Income from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for ATRA's Competitors
Income from Cont. Operations Growth for Atara Biotherapeutics,'s Suppliers
Income from Cont. Operations Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2018 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2018
Jazz Pharmaceuticals Plc  135.05 %$ 135.047 millions
Inogen Inc  123.93 %$ 123.930 millions
Bristol Myers Squibb Co  123.36 %$ 123.364 millions
Baxter International Inc  119.35 %$ 119.355 millions
Amedisys Inc  115.18 %$ 115.183 millions
Pro Dex Inc  114.81 %$ 114.809 millions
Innoviva, Inc.  111.08 %$ 111.078 millions
Intricon Corp  107.52 %$ 107.525 millions
Lilly Eli & Co  106.89 %$ 106.893 millions
Abiomed Inc  104.57 %$ 104.575 millions
Mylan N.v.  100.11 %$ 100.113 millions
Medpace Holdings, Inc.  96.37 %$ 96.369 millions
Lhc Group, Inc  93.80 %$ 93.801 millions
Hill-rom Holdings, Inc.  89.92 %$ 89.916 millions
National Healthcare Corp  88.55 %$ 88.546 millions
Utah Medical Products Inc  86.69 %$ 86.692 millions
Biospecifics Technologies Corp  85.76 %$ 85.759 millions
Spring Pharmaceutical Group, Inc.  82.42 %$ 82.417 millions
U S Physical Therapy Inc  80.15 %$ 80.149 millions
Supernus Pharmaceuticals Inc  75.50 %$ 75.497 millions
Laboratory Corp Of America Holdings  73.94 %$ 73.937 millions
Hca Healthcare, Inc.  69.06 %$ 69.057 millions
Abbvie Inc.  68.42 %$ 68.424 millions
Techcare Corp.  66.40 %$ 66.399 millions
Zimmer Biomet Holdings, Inc.  64.07 %$ 64.069 millions
Icu Medical Inc  61.03 %$ 61.029 millions
Dynatronics Corp  58.88 %$ 58.875 millions
Exelixis, Inc.  55.60 %$ 55.600 millions
Cambrex Corp  55.22 %$ 55.215 millions
Regeneron Pharmaceuticals Inc  53.14 %$ 53.136 millions


     
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

KFFB's Profile

Stock Price

KFFB's Financials

Business Description

Fundamentals

Charts & Quotes

KFFB's News

Suppliers

KFFB's Competitors

Customers & Markets

Economic Indicators

KFFB's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071